Replies to post #186587 on Biotech Values

[DewDiligence]

…the very low number of scripts being reported are for 92% of the HCV population. What is not being reported is the scripts for 8% of the population.

That’s not an especially helpful metric for investors. Rather, what investors are trying to estimate is ABBV’s market share of patients currently being treated.